Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial

Dyne Therapeutics reported additional one-year clinical data from its Phase 1/2 ACHIEVE trial, showing functional improvement in participants compared to baseline, placebo, and a matched natural history cohort. The data indicated continued improvement at 6 months in video hand opening time (vHOT), an early indicator of clinical benefit with z-basivarsen in DM1. The company anticipates topline data from the ACHIEVE registrational expansion cohort in Q1 2027, with a potential submission for U.S. Accelerated Approval planned for Q3 2027.